5th India Pharmaceutical Forum 2020

Session 1 : Welcome and Setting the Context- Mr Sudarshan Jain, IPA

Session 1 : Inaugural Address- Mr Satish Reddy, Dr Reddy&#039;s

Session 1 : Release of IPA Guidelines on Market Complaints

Session 3 : Quality and Patient Centricity- Mr Jeff Francer, AAM

Session 4 : CDER / OC / OMQ Update and Recent Cross Contamination Case Studies- Mr Jeff Francer, AAM

Session 4 : Surveillance Inspections and Recent Trends- Mr Jay Jariwala, USFDA (India)

Session 5 : Quality by Design for Robust Product- Dr James Pound, MHRA

Session 5 : Quality by Design for Robust Product- Mr Vipul Doshi, Cadila Healthcare

Session 6 : Culture Transformation - Best Practices- Dr Samantha Atkinson, MHRA

Session 6 : Culture Transformation - Best Practices- Ms Sue Schniepp, PDA

Session 6 : Culture Transformation - Best Practices- Mr Johnny Mikell, Lupin

Session 7 : Commitment to Quality in Pharmaceutical Development and Commercial Manufacturing- Dr Stelios Tsinontides, USFDA

Session 7 : Cost of Quality- Dr Ranjana Pathak, Cipla

Session 8 : Global Best Practices in Capability Building- Mr Jaidev Rajpal, McKinsey &amp; Co.

Session 8 : Digital Technologies in Pharma Operations for Improved Quality- Mr Matthias Spiegl, McKinsey

Session 9 : Nitrosamine Impurities - Current Status and Expectations- Dr Declan Byrne, EDQM

Session 9 : Nitrosamine Impurities - Current Status and Expectations- Dr Milind Joshi, J B Chemicals